drugset / Trial / NCT06019702
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms
Phase 1
Recruiting
20 enrolled
Sir Run Run Shaw Hospital
Hangzhou Neoantigen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, feasibility, and efficacy of personalized mRNA vaccine iNeo-Vac-R01 alone in subjects with advanced digestive system neoplasms.
Timeline
- Start
- 2023-09-08
- Primary completion
- 2027-08-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | iNeo-Vac-R01 | Messenger RNA (mRNA) | 50 ug | Other |
| Subject | iNeo-Vac-R01 | Messenger RNA (mRNA) | 100 ug | Other |
| Subject | iNeo-Vac-R01 | Messenger RNA (mRNA) | 150 ug | Other |